Placeholder Banner

BIO Expands Cooperation with China-Based Pharma Group

June 22, 2017

San Diego, CA (June 22, 2017) – Today Biotechnology Innovation Organization announced the signing of a Memorandum of Understanding for Cooperation (MOU) with the Pharmaceutical Association Committee (RDPAC). RDPAC is a non-profit organization located within the China Association of Enterprises with Foreign Investment (CAEFI) and has a membership of 38 multi-national companies with pharmaceutical R&D capabilities in China.

The MOU will further enable the two associations to collaborate closely on activities and issues of common interest, as well as to further develop partnerships in China.

Joe Damond, the Executive Vice President, International Affairs at BIO, said: “This agreement continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts to advance advocacy and outreach for the biotechnology industry in China. Together we will continue to highlight the value of this industry in benefiting society and addressing global health challenges.”

Future cooperative efforts will focus on several areas, including expert-level exchange, research, and workshops. BIO and RDPAC are committed to creating an environment that promotes innovation and greater integration of China into the global biopharmaceutical ecosystem.

 

###

Discover More
Seed technology companies comply with Mexico’s biosafety regulations, and Mexico should do the same, BIO said today in its response to the panel set up to determine if Mexico’s ban on imports of genetically modified corn violate its commitments…
BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset: “As a…
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…